Merck's Keytruda Meets Main Endpoints in Endometrial Carcinoma Study
03 Februar 2023 - 1:29PM
Dow Jones News
By Colin Kellaher
Merck & Co. on Friday said a Phase 3 study of its
blockbuster cancer drug Keytruda met its primary endpoint in
certain patients with endometrial carcinoma, the most common type
of gynecologic cancer in the U.S.
The Kenilworth, N.J., drugmaker said Keytruda plus chemotherapy
significantly improved progression-free survival versus standard of
care chemotherapy alone as first-line treatment for patients with
stage III-IV or recurrent endometrial carcinoma, regardless of
mismatch repair status.
Merck said patients with advanced-stage or recurrent endometrial
cancer currently face a poor prognosis with limited treatment
options.
Merck is studying Keytruda, a cancer drug that harnesses a
patient's immune system to fight tumors, in a raft of trials across
a wide variety of cancers and treatment settings.
The drug, which is approved in dozens of indications around the
world, generated sales of nearly $21 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 03, 2023 07:14 ET (12:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
